Results: 11
Correction to: Ivosidenib: First Global Approval.
- Published in:
- Drugs, 2019, v. 79, n. 1, p. 107, doi. 10.1007/s40265-018-1050-z
- By:
- Publication type:
- Article
Correction to: Moxetumomab Pasudotox: First Global Approval.
- Published in:
- Drugs, 2019, v. 79, n. 1, p. 105, doi. 10.1007/s40265-018-1049-5
- By:
- Publication type:
- Article
Emapalumab: First Global Approval.
- Published in:
- Drugs, 2019, v. 79, n. 1, p. 99, doi. 10.1007/s40265-018-1046-8
- By:
- Publication type:
- Article
Lorlatinib: First Global Approval.
- Published in:
- Drugs, 2019, v. 79, n. 1, p. 93, doi. 10.1007/s40265-018-1041-0
- By:
- Publication type:
- Article
Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease.
- Published in:
- Drugs, 2019, v. 79, n. 1, p. 75, doi. 10.1007/s40265-018-1040-1
- By:
- Publication type:
- Article
Recent Developments in Male Contraception.
- Published in:
- Drugs, 2019, v. 79, n. 1, p. 11, doi. 10.1007/s40265-018-1038-8
- By:
- Publication type:
- Article
Targeting Angiogenesis in Colorectal Carcinoma.
- Published in:
- Drugs, 2019, v. 79, n. 1, p. 63, doi. 10.1007/s40265-018-1037-9
- By:
- Publication type:
- Article
Revefenacin: First Global Approval.
- Published in:
- Drugs, 2019, v. 79, n. 1, p. 85, doi. 10.1007/s40265-018-1036-x
- By:
- Publication type:
- Article
Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice.
- Published in:
- Drugs, 2019, v. 79, n. 1, p. 43, doi. 10.1007/s40265-018-1035-y
- By:
- Publication type:
- Article
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives.
- Published in:
- Drugs, 2019, v. 79, n. 1, p. 21, doi. 10.1007/s40265-018-1033-0
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer.
- Published in:
- Drugs, 2019, v. 79, n. 1, p. 1, doi. 10.1007/s40265-018-1032-1
- By:
- Publication type:
- Article